Physiomics (PYC) Competitors GBX 0.69 +0.02 (+2.52%) (As of 03:27 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines PYC vs. ROQ, FAB, OBD, EVG, MTFB, BSFA, DEST, TCF, VAL, and RENEShould you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Roquefort Therapeutics (ROQ), Fusion Antibodies (FAB), Oxford BioDynamics (OBD), Evgen Pharma (EVG), Motif Bio (MTFB), BSF Enterprise (BSFA), Destiny Pharma (DEST), Theracryf (TCF), ValiRx (VAL), and ReNeuron Group (RENE). These companies are all part of the "biotechnology" industry. Physiomics vs. Roquefort Therapeutics Fusion Antibodies Oxford BioDynamics Evgen Pharma Motif Bio BSF Enterprise Destiny Pharma Theracryf ValiRx ReNeuron Group Physiomics (LON:PYC) and Roquefort Therapeutics (LON:ROQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Do insiders and institutionals believe in PYC or ROQ? 1.7% of Roquefort Therapeutics shares are held by institutional investors. 4.2% of Physiomics shares are held by insiders. Comparatively, 60.4% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, PYC or ROQ? Physiomics has higher revenue and earnings than Roquefort Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhysiomics£900.71K1.52N/AN/AN/ARoquefort Therapeutics£637.008,008.52-£1.54M-£0.01-395.00 Does the media favor PYC or ROQ? In the previous week, Physiomics' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score. Company Overall Sentiment Physiomics Neutral Roquefort Therapeutics Neutral Which has more volatility & risk, PYC or ROQ? Physiomics has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Is PYC or ROQ more profitable? Roquefort Therapeutics has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Roquefort Therapeutics' return on equity of -27.05% beat Physiomics' return on equity.Company Net Margins Return on Equity Return on Assets Physiomics-106.80% -149.67% -76.38% Roquefort Therapeutics N/A -27.05%-15.86% Does the MarketBeat Community believe in PYC or ROQ? Physiomics received 80 more outperform votes than Roquefort Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformPhysiomicsOutperform Votes8055.56% Underperform Votes6444.44% Roquefort TherapeuticsN/AN/A SummaryRoquefort Therapeutics beats Physiomics on 6 of the 10 factors compared between the two stocks. Ad Colonial MetalsA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Physiomics News Delivered to You Automatically Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYC vs. The Competition Export to ExcelMetricPhysiomicsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£1.37M£137.13M£5.14B£1.48BDividend Yield6.20%3.50%5.08%11.33%P/E Ratio-13.83326.96127.091,539.50Price / Sales1.5215,712.531,227.09196,974.97Price / Cash4.2112.0240.1334.53Price / BookN/A6.976.932.87Net IncomeN/A-£18.75M£119.36M£158.76M7 Day Performance-3.85%0.17%0.99%-0.40%1 Month PerformanceN/A7.22%-4.25%-0.83%1 Year Performance-60.29%28.27%31.18%98.79% Physiomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYCPhysiomicsN/AGBX 0.69+2.5%N/A-67.0%£1.41M£900,707.00-13.8310Gap UpROQRoquefort TherapeuticsN/AGBX 3.95-1.3%N/A-41.3%£5.10M£637.00-395.009Gap UpFABFusion AntibodiesN/AGBX 4.20-1.2%N/A+26.1%£4.01M£1.14M-102.5848Gap UpOBDOxford BioDynamicsN/AGBX 1.15-4.8%N/A-96.7%£3.59M£176,000.00-19.1745Gap DownEVGEvgen PharmaN/AGBX 0.80flatN/A-51.7%£3.42MN/A-80.0010MTFBMotif BioN/AGBX 0.50flatN/AN/A£3.28MN/A-0.036BSFABSF EnterpriseN/AGBX 2.88flatN/A-69.7%£2.97MN/A-143.7512Gap DownDESTDestiny PharmaN/AGBX 3-30.1%N/A-96.1%£2.87M£135,028.00-50.0024Gap DownHigh Trading VolumeTCFTheracryfN/AGBX 0.54+2.5%N/AN/A£2.30MN/A-52.0010Gap UpHigh Trading VolumeVALValiRxN/AGBX 1.68flatN/A-83.7%£2.22MN/A-83.505,450RENEReNeuron GroupN/AGBX 3.38-2.2%N/A-6.9%£1.93M£783,000.00-37.502News CoverageGap Down Related Companies and Tools Related Companies Roquefort Therapeutics Competitors Fusion Antibodies Competitors Oxford BioDynamics Competitors Evgen Pharma Competitors Motif Bio Competitors BSF Enterprise Competitors Destiny Pharma Competitors Theracryf Competitors ValiRx Competitors ReNeuron Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:PYC) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredAmerica’s Pro-Crypto AgendaCash In On the Pro-Crypto America 27 experts reveal their top picks for 2025 Crypto 101 Media | SponsoredA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Physiomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
